APR 15, 2017 6:26 PM PDT

Aspirin Therapy Not As Effective As Previously Thought

WRITTEN BY: Kara Marker

How effective is aspirin for treating peripheral vascular disease, really? A large-scale meta-analysis introduces the idea that aspirin could be not very effective at all, potentially even harmful. The new study calls for more experiments to make a definitive statement on the efficacy of aspirin for treating peripheral vascular disease (PVD) and other heart conditions.

PVD consists of blood vessel maladies outside of those in the heart and brain - arteries that carry blood to the limbs, stomach, and kidneys. Two forms of PVD determine a range of possible symptoms; functional PVD involves no physical damage to the blood vessels and is characterized by fluctuating muscle spasms, and organic PVD describes structural changes to blood vessels, causing inflammation and tissue damage. Overall PVD is accompanied by a reduction in blood flow, affecting more than eight million people in the United States.

Aspirin is a classic example of a common drug used to treat heart and blood vessel conditions, like PVD. This drug prevents blood clots from forming, subsequently reducing the risk of adverse cardiac events. However, aspirin’s mechanism of action can backfire, sometimes increasing a person’s risk of hemorrhagic stroke or internal bleeding.

Cardiologist Anthony A Bavry, MD, says that many PVD patients “may not be deriving the benefits from aspirin that they expect to be getting.”

The University of Florida study included a meta-analysis of 11 aspirin therapy trials including more than six thousand PVD patients participating in studies. Statistics gleaned from the 11 trials  showed that aspirin had “no significant effect on death rates and incidents of stroke, heart attack, or major cardiac events.”

"Aspirin might not be a miracle drug for certain patients,” said co-author Ahmed N. Mahmoud, MD. “We need to reconsider the evidence, and see who benefits from aspirin therapy and who does not.”

The present study was published in the journal PLOS One.

Sources: University of Florida, American Heart Association

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
APR 27, 2020
Cardiology
APR 27, 2020
Almost Half of College Female Athletes Have High Blood Pressure
According to the World Health Organization (WHO) an estimated 1.13 billion people worldwide have hypertension, or high b ...
APR 30, 2020
Cardiology
APR 30, 2020
Nighttime Blood Pressure Changes Linked to Cerebrovascular Disease and Impaired Cognition
When most people go to sleep, their blood pressure decreases, or dips, compared to daytime values. However, for some, a ...
MAY 12, 2020
Drug Discovery & Development
MAY 12, 2020
Does Herbal Drink from Madagascar Cure COVID-19?
Andry Rajoelina, the president of Madagascar, an island off the coast of Southern Africa, has made claims that his count ...
MAY 12, 2020
Cardiology
MAY 12, 2020
Beverages Sweetened with High-fructose Corn Syrup Linked to Reduced Renal Blood Flow
It is well-accepted that beverages with high sugar concentrations—such as high-fructose containing soda- —ar ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
Loading Comments...